Imfinzi (durvalumab) is the First Immunotherapy to Demonstrate Significant Overall Survival Benefits in Unresectable, Stage III Non-Small Cell Lung Cancer
Biospace,
Phase III PACIFIC data presented at the IASLC 2018 World Conference on Lung Cancer in Toronto shows 32 per cent reduced risk of…